Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study

Neovascular age-related macular degeneration (nAMD) leads to visual impairment if not treated promptly. Intravitreal anti-VEGF drugs have revolutionized nAMD treatment in the past two decades. We evaluated outcomes of nAMD. A real-life population-based cohort study. The data included parameters for age, sex, age at diagnosis, laterality, chronicity, symptoms, outcomes, lens status, and history intravitreal injections. total 1088 eyes (827 patients) with were included. Visual acuity was stable or improved 984 (90%) after an average 36 ± 25 months follow-up. Bevacizumab first-line drug 1083 (99.5%) eyes. Vision ≥15 ETDRS letters 377 (35%), >5 309 (28%), (±5 letters) 298 (27%) treatment. loss 5 ≤ 15 44 (4%) 60 (6%) noted. At diagnosis nAMD, 110 out 827 patients (13%) fulfilled criteria impairment, whereas 179 (22%) visually impaired Improvement stabilization vision noted 90% anti-VEGF-treated In addition, agents are crucial diminishing nAMD-related impairment.